Is total arch replacement associated with an increased risk after acute type A dissection?
Acute type A aortic dissection (AADA)
ascending aorta replacement (AAR)
total aortic arch replacement (TAAR)
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
20
11
2020
Statut:
ppublish
Résumé
The surgical strategy for acute type A aortic dissection (AADA) usually consists of reconstruction of the tear-lesion in the affected part of the ascending aorta. The optimal strategy either to replace the ascending aorta (AAR) or to replace the ascending aorta and the total aortic arch (TAAR) is still under debate. Our study compares the 30-day mortality between AAR and TAAR in AADA surgery. In this retrospective observational study, we analysed a total patient cohort of 339 patients who underwent surgery for AADA from January 2001 until December 2016. A propensity score-matched analysis between the AAR- and the TAAR-group with 43 patients for each subgroup was subsequently carried out. A multivariable analysis was performed to identify risk-factors for the 30-d-mortality. The 30-day mortality was defined as the primary end-point and long-term survival was the secondary endpoint. In 292 (86.1%) patients AAR and in 47 (13.9%) patients TAAR was performed for emergent AADA. Patients were older (P=0.049) in the AAR group. The median log Euro-SCORE was 25.5% (12.7; 41.7) for AAR and 19.7% (11.7; 32.2) for the TAAR patient cohort (P=0.12). Operative time, cardiopulmonary bypass- (CPB), cross-clamp- and ischemic time were significantly longer in the TAAR group (P<0.001). The overall 30-day mortality-rate was 17.7% (n=60) but was not significantly different between the two groups (P=0.27). Forty-nine (16.8%) patients died in the AAR and 11 patients (23.4%) in the TAAR group. After propensity-score matching, no difference in mortality was seen between the subgroups as well (P=0.44). Multivariable analysis identified the Euro-SCORE, long operation-time, postoperative dialysis and arrhythmia and administration of red blood cell concentrates as risk factors for 30-day mortality, but not for TAAR versus AAR. The therapeutic goal in AADA surgery should be the complete restoration of the aorta to avoid further long-term complications and re-operations. Though 30-day mortality and postoperative co-morbidity for AAR are comparable to those in TAAR after treatment of AADA in our analysis, decision-making for the surgical strategy should weigh the operative risk of TAAR against the long-term outcome.
Sections du résumé
BACKGROUND
BACKGROUND
The surgical strategy for acute type A aortic dissection (AADA) usually consists of reconstruction of the tear-lesion in the affected part of the ascending aorta. The optimal strategy either to replace the ascending aorta (AAR) or to replace the ascending aorta and the total aortic arch (TAAR) is still under debate. Our study compares the 30-day mortality between AAR and TAAR in AADA surgery.
METHODS
METHODS
In this retrospective observational study, we analysed a total patient cohort of 339 patients who underwent surgery for AADA from January 2001 until December 2016. A propensity score-matched analysis between the AAR- and the TAAR-group with 43 patients for each subgroup was subsequently carried out. A multivariable analysis was performed to identify risk-factors for the 30-d-mortality. The 30-day mortality was defined as the primary end-point and long-term survival was the secondary endpoint.
RESULTS
RESULTS
In 292 (86.1%) patients AAR and in 47 (13.9%) patients TAAR was performed for emergent AADA. Patients were older (P=0.049) in the AAR group. The median log Euro-SCORE was 25.5% (12.7; 41.7) for AAR and 19.7% (11.7; 32.2) for the TAAR patient cohort (P=0.12). Operative time, cardiopulmonary bypass- (CPB), cross-clamp- and ischemic time were significantly longer in the TAAR group (P<0.001). The overall 30-day mortality-rate was 17.7% (n=60) but was not significantly different between the two groups (P=0.27). Forty-nine (16.8%) patients died in the AAR and 11 patients (23.4%) in the TAAR group. After propensity-score matching, no difference in mortality was seen between the subgroups as well (P=0.44). Multivariable analysis identified the Euro-SCORE, long operation-time, postoperative dialysis and arrhythmia and administration of red blood cell concentrates as risk factors for 30-day mortality, but not for TAAR versus AAR.
CONCLUSIONS
CONCLUSIONS
The therapeutic goal in AADA surgery should be the complete restoration of the aorta to avoid further long-term complications and re-operations. Though 30-day mortality and postoperative co-morbidity for AAR are comparable to those in TAAR after treatment of AADA in our analysis, decision-making for the surgical strategy should weigh the operative risk of TAAR against the long-term outcome.
Identifiants
pubmed: 33209385
doi: 10.21037/jtd-20-871
pii: jtd-12-10-5517
pmc: PMC7656345
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5517-5531Informations de copyright
2020 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-871). The authors have no conflicts of interest to declare.
Références
Ann Cardiothorac Surg. 2016 Jul;5(4):383-8
pubmed: 27563552
J Thorac Cardiovasc Surg. 2020 Apr;159(4):1201-1211
pubmed: 31208809
Mayo Clin Proc. 2004 Feb;79(2):176-80
pubmed: 14959911
Tex Heart Inst J. 2011;38(6):694-700
pubmed: 22199439
Ann Thorac Surg. 2007 Jan;83(1):55-61
pubmed: 17184630
J Thorac Cardiovasc Surg. 2012 Aug;144(2):300-7
pubmed: 22078710
Ann Thorac Surg. 2019 Nov;108(5):1330-1336
pubmed: 31158351
Ann Cardiothorac Surg. 2018 May;7(3):437-442
pubmed: 30155425
Ann Thorac Surg. 2011 Apr;91(4):1147-52
pubmed: 21440135
Circulation. 2006 Jul 4;114(1 Suppl):I350-6
pubmed: 16820599
Circulation. 2013 Sep 10;128(11 Suppl 1):S180-5
pubmed: 24030404
Minim Invasive Ther Allied Technol. 2015;24(5):311-6
pubmed: 26358834
Eur J Cardiothorac Surg. 2017 Jan;51(suppl 1):i35-i39
pubmed: 28108567
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
G Ital Cardiol. 1999 Aug;29(8):898-909
pubmed: 10488452
J Am Coll Cardiol. 2014 May 6;63(17):1796-803
pubmed: 24412454
Ann Thorac Surg. 2005 Aug;80(2):523-9
pubmed: 16039197
J Thorac Cardiovasc Surg. 2010 Oct;140(4):784-9
pubmed: 20176372
Thorac Cardiovasc Surg. 2017 Mar;65(2):77-84
pubmed: 26975809
Eur J Cardiothorac Surg. 2020 Apr 1;57(4):669-675
pubmed: 31504378
J Am Coll Cardiol. 2002 Aug 21;40(4):685-92
pubmed: 12204498
J Am Coll Cardiol. 2015 Jun 23;65(24):2628-2635
pubmed: 26088302
Eur J Cardiothorac Surg. 2018 Mar 1;53(3):519-524
pubmed: 29136132